[1]
|
[1]FERLAY J S I.Incidence/Mortality Data.GLOBOCAN2012 v1.0, Cancer Incidence and Mortality Worldwide:IARC Cancer Base No.11[Internet].International Agency for Research on Cancer, Lyon, France, 2013.Available from URL:http://globocan.iarc.fr.
|
[2]
|
[2]GLOBOCAN 2012:Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012[EB/OL].http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx, 2013-12-12.
|
[3]陈万青, 张思维, 曾红梅, 等.中国2010年恶性肿瘤发病与死亡[J].中国肿瘤, 2014, 23 (1) :1-10.
|
[4]石岳泉, 杨向红.非小细胞肺癌的驱动基因及其临床意义[J].中国肺癌杂志, 2014, 17 (6) :481-486.
|
[5]
|
[5]SHI Y, AU J S, THONGPRASERT S, et al.A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER) [J].J Thorac Oncol, 2014, 9 (2) :154-162.
|
[6]
|
[6]LI H, PAN Y, LI Y, et al.Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose[J].Lung Cancer, 2013, 79 (1) :8-13.
|
[7]
|
[7]KIM H R, KIM D J, KANG D R, et al.Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer[J].J Clin Oncol, 2013, 31 (6) :731-737.
|
[8]
|
[8]LINDEMAN N I, CAGLE P T, BEASLEY M B, et al.Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors:guideline from the college of american pathologists, international association for the study of lung cancer, and association for molecular pathology[J].J Thorac Oncol, 2013, 8 (7) :823-859.
|
[9]
|
[9]ROSELL R, CARCERENY E, GERVAIS R, et al.Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation positive non small cell lung cancer (EURTAC) :a multicentre, open label, randomised phase3 trial[J].Lancet Oncol, 2012, 13 (3) :239-246.
|
[10]张娜, 王文彤, 陶遵威.非小细胞肺癌分子靶向治疗的最新研究进展[J].天津药学, 2015, 27 (1) :44-46.
|
[11]
|
[11]COSTA C, MOLINA M A, DROZDOWSKYJ A, et al.The impact of EGFR T790M mutations and BIM m RNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial[J].Clin Cancer Res, 2014, 20 (7) :2001-2010.
|
[12]
|
[12]GAZDAR A F.EGFR mutations in lung cancer:Different frequencies for different folks[J].J Thorac Oncol, 2014, 9 (2) :139-140.
|
[13]
|
[13]NAKAMURA R, INAGE Y, TOBITA R, et al.Epidermal growth factor receptor mutations:effect on volume doubling time of non-small-cell lung cancer patients[J].J Thorac Oncol, 2014, 29 (9) :1294-1304.
|
[14]
|
[14]XU Z, HANG J, HU J, et al.Gefitinib, an EGFR tyrosine kinase inhibitor, activates autophagy through AMPK in human lung cancer cells[J].J Buon, 2014, 19 (2) :466-473.
|
[15]赵建国, 徐农.非小细胞肺癌的分子分型[J].实用肿瘤杂志, 2014, 29 (5) :399-403.
|
[16]
|
[16]LI Y, LI Y, YANG T, et al.Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS genemutations in 208 Chinese patients with nonsmall cell lung cancer[J].Plos One, 2013, 8 (1) :e52093.
|
[17]
|
[17]KRIS M G, JOHNSON B E, BERRY L D, et al.Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs[J].Jama, 2014, 311 (19) :1998-2006.
|
[18]王辉, 王英浩, 陈晓英.放射治疗联合厄洛替尼对肺腺癌脑转移的疗效分析[J].中国医药导刊, 2016, 18 (2) :137-139.
|
[19]张帆.EGFR-TKIs联合全脑放疗与全脑放疗治疗肺腺癌脑转移疗效分析[J].中国医学工程, 2014, 22 (12) :71-72.
|
[20]陈雪琴, 杨邵瑜, 黄杰, 等.肺腺癌患者驱动基因表达及生存分析[J].实用肿瘤杂志, 2016, 31 (3) :246-269.
|
[21]周荻, 徐欣, 谢华英, 等.全脑放疗联合靶向治疗与同步放、化疗治疗非小细胞肺癌脑转移疗效分析[J].上海交通大学学报 (医学版) , 2013, 33 (4) :480-484.
|